This longer gap increases the risk of appetite return and weight regain, so most providers avoid it unless specifically indicated for side effect management
Given as a lowdose subcutaneous injection ahead of anticipated intimacy, this nonFDAapproved protocol is offered under informed consent and tailored around each clients health, triggers, and relationship goals
It is not currently approved for type 2 diabetes in the US, though Lilly has stated its intention to file for that indication during 2026
Nausea, the most common complaint, peaked around weeks 6-8 and typically resolved by week 12
When administered professionally, glutathione is very safe
Direct head-to-head Phase 3 comparison data from the TRIUMPH-3 trial is not yet available